Bioverativ Inc.
Bioverativ develops and commercializes drug therapies for the treatment of hemophilia and other blood disorders.
Business Model:
Revenue: $1.2B
Employees: 201-500
Rankings
Industries / Tags:
Detailed Bioverativ Inc. Information
Bioverativ Inc. was acquired by
Sanofi.
The acquisition happend on 2018-01-22.
Details of the transaction were not public
Acquirer
Geographic Data
Address: 225 2nd Ave
City: Waltham
State: MA
Zip: 02451
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Metrics
4,792,169Website Global Rank
1,831Website Monthly Traffic
Twitter Followers
Description
Bioverativ develops and commercializes drug therapies for the treatment of hemophilia and other blood disorders.
Contact Phone:
Contact Email:
Bioverativ Inc. went public on 1/13/2017 on the NASDAQ
Listed Exchange:
NASDAQ
IPO Date:
1/13/2017
Ticker Symbol:
BIVV
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors |
|---|
| Announced Date | Name | Price |
|---|---|---|
| 5/2017 | True North Therapeutics |
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
